Replies to post #22898 on RespireRx Pharmaceuticals Inc (RSPI)

[neuroinv]

Unfortunately, two factors make the King/PT deal pretty much irrelevant as a marker for RD now:

1) It was in late 2005. The climate is much different now.
2) Remoxy was ready for Phase III. Any drug that has finished Phase IIb has great leverage. CX717 still needs to go through Phase IIb, establish optimal dosing, etc.

Any deal will include the BP paying for whatever R&D RD needs from this point forwards, and even the milestones and royalty rates could be fine. It's the upfront cash companies are pulling back on.


NeuroInvestment